Verona Pharma Aims to Deliver COPD Patients a New Treatment Option – Submits Ensifentrine NDA to US FDA!

Verona Pharma plc (Nasdaq: VRNA) is proud to announce their submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval of ensifentrine to the maintenance treatment of chronic obstructive pulmonary disease (COPD) patients. If the new drug is approved, it would be the first novel medication to be made available in over 10 years- a major breakthrough for the medical industry! Combining bronchodilator and non-steroidal anti-inflammatory actions, ensifentrine possesses a unique dual inhibitory action on phosphodiesterase 3 and 4. This new treatment is poised to revolutionize COPD therapies, and Verona Pharma hopes it will bring hope and relief to those suffering from the condition.

Verona Pharma is excited to announce the submission of the New Drug Application (NDA) for ensifentrine, a potential first-in-class therapy for patients with chronic obstructive pulmonary disease (COPD). This is a major milestone in the company’s mission to bring new treatment options to the millions of symptomatic COPD patients in the US. The NDA is based on the positive Phase 3 ENHANCE study and other clinical data gathered from 3,000 subjects. Verona Pharma looks forward to working with the FDA during the review process.

Leave a Comment